China’s biotechnology stocks are shaking off a four-year slump to be among the hottest performers in Asia this year. The Hang Seng Biotech Index has surged around 60% this year in what some are calling the “DeepSeek moment” for the sector. One of the companies riding the rally, is Innovent Biologics. Its Global Chief Business Officer Samuel Zhang says the company’s product pipeline is full, and puts it in a position for years of steady growth. He spoke with David Ingles and Yvonne Man on “Bloomberg: The China Show.”
